Analysts Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Target Price at $23.20

Stoke Therapeutics, Inc. (NASDAQ:STOK) has earned a consensus rating of “Buy” from the seven brokerages that are currently covering the firm, MarketBeat reports. Five research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $23.20.

A number of research analysts have recently issued reports on the company. HC Wainwright decreased their target price on Stoke Therapeutics from $47.00 to $35.00 and set a “buy” rating on the stock in a research report on Wednesday, May 14th. Needham & Company LLC reiterated a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, April 9th. Cantor Fitzgerald upgraded Stoke Therapeutics to a “strong-buy” rating in a research report on Wednesday, May 14th. Finally, Chardan Capital reiterated a “buy” rating and set a $24.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, March 19th.

Insider Activity at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 3,884 shares of the firm’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $33,674.28. Following the completion of the sale, the insider now directly owns 63,962 shares of the company’s stock, valued at $554,550.54. This trade represents a 5.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Edward M. Md Kaye sold 10,382 shares of the firm’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $90,011.94. Following the completion of the sale, the director now directly owns 148,253 shares of the company’s stock, valued at $1,285,353.51. This trade represents a 6.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 24,748 shares of company stock valued at $225,687. 11.30% of the stock is owned by insiders.

Institutional Trading of Stoke Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of STOK. Toronto Dominion Bank acquired a new stake in shares of Stoke Therapeutics during the 4th quarter worth about $35,001,000. RTW Investments LP boosted its holdings in Stoke Therapeutics by 10.1% during the 4th quarter. RTW Investments LP now owns 5,123,525 shares of the company’s stock valued at $56,512,000 after acquiring an additional 471,240 shares during the period. Checkpoint Capital L.P. boosted its holdings in Stoke Therapeutics by 139.3% during the 1st quarter. Checkpoint Capital L.P. now owns 730,717 shares of the company’s stock valued at $4,859,000 after acquiring an additional 425,330 shares during the period. Erste Asset Management GmbH purchased a new position in Stoke Therapeutics during the 1st quarter valued at about $2,670,000. Finally, Jacobs Levy Equity Management Inc. purchased a new position in Stoke Therapeutics during the 1st quarter valued at about $2,376,000.

Stoke Therapeutics Trading Up 2.4%

Stoke Therapeutics stock opened at $11.14 on Thursday. Stoke Therapeutics has a 12 month low of $5.35 and a 12 month high of $17.58. The stock’s 50 day simple moving average is $8.77 and its two-hundred day simple moving average is $9.65. The firm has a market cap of $608.21 million, a PE ratio of -5.30 and a beta of 1.09.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The business had revenue of $22.61 million for the quarter, compared to analyst estimates of $4.20 million. On average, equities research analysts forecast that Stoke Therapeutics will post -2.01 EPS for the current year.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.